- Email: [email protected]
Reclassifying Lung Cancer and Molecular Diagnostic
Annals of Oncology 25 (Supplement 4): iv23, 2014 doi:10.1093/annonc/mdu304.1
special symposium: the evolving role of systemic treatment in advanced NSCLC 62IN
R. Govindan, S. Devarakonda Division Of Oncology, Washington University School of Medicine, St. Louis, MO, USA
abstracts
Lung cancer has traditionally been classified based on tumor histology. However, with the advent of targeted therapies, the utility of this classification scheme in guiding
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_4/iv23/2238097 by guest on 26 October 2019
RECLASSIFYING LUNG CANCER AND MOLECULAR DIAGNOSTIC
clinical decisions is limited. Several studies have consistently highlighted the molecular heterogeneity underlying lung cancers. Using gene-expression data, investigators have classified adenocarcinomas (LUAD) into “bronchoid”, “squamoid”, and “magnoid” subtypes, and squamous cell cancers (SQCC) into “primitive”, “classical”, “secretory”, and “basal” subtypes. Further, next-generation sequencing data from the Cancer Genome Atlas (TCGA), have confirmed the reproducibility of these subtypes, and have also facilitated a study of the mutational, gene copy-number, and epigenetic features underlying these tumors. Similarly, it has also shown large cell lung cancer can be subdivided based on the molecular features. It is conceivable that classifying cancers based on common transcriptional features and biological themes identify may identify subgroups of patients at risk for recurrence following surgical resection. Disclosure: R. Govindan: Consultant for: Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Merck, Bayer, Covidien, Bristol Myers-Squibb, Genentech (Roche), Mallinckrodt Honoraria received. All other authors have declared no conflicts of interest.
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
special symposium: the evolving role of systemic treatment in advanced NSCLC 62IN
R. Govindan, S. Devarakonda Division Of Oncology, Washington University School of Medicine, St. Louis, MO, USA
abstracts
Lung cancer has traditionally been classified based on tumor histology. However, with the advent of targeted therapies, the utility of this classification scheme in guiding
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_4/iv23/2238097 by guest on 26 October 2019
RECLASSIFYING LUNG CANCER AND MOLECULAR DIAGNOSTIC
clinical decisions is limited. Several studies have consistently highlighted the molecular heterogeneity underlying lung cancers. Using gene-expression data, investigators have classified adenocarcinomas (LUAD) into “bronchoid”, “squamoid”, and “magnoid” subtypes, and squamous cell cancers (SQCC) into “primitive”, “classical”, “secretory”, and “basal” subtypes. Further, next-generation sequencing data from the Cancer Genome Atlas (TCGA), have confirmed the reproducibility of these subtypes, and have also facilitated a study of the mutational, gene copy-number, and epigenetic features underlying these tumors. Similarly, it has also shown large cell lung cancer can be subdivided based on the molecular features. It is conceivable that classifying cancers based on common transcriptional features and biological themes identify may identify subgroups of patients at risk for recurrence following surgical resection. Disclosure: R. Govindan: Consultant for: Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Merck, Bayer, Covidien, Bristol Myers-Squibb, Genentech (Roche), Mallinckrodt Honoraria received. All other authors have declared no conflicts of interest.
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].